In a report published in the online edition of The Lancet Dr. Robert J. Motzer, from Sloan-Kettering Cancer Center in New York reported that treatment with everolimus improved the progression-free survival of patients with advanced kidney cancer who had not responded to other treatments.
The study involved 410 patients with kidney cancer that has metastasized to other parts of the body despite treatments with sunitab and/or sorfenib. Patients received either everolimus or a placebo once a day in addition to supportive care.
Everolimus, which has already been U.S. Food and Drug Administration approved as Certican, is indicated for the prevention of heart transplant rejection and if new approval is granted as a cancer drug, use of the agent would greatly expand.
The progression rate of the kidney cancer was found to be 37% in the everolimus group as compared to 65% in the placebo group with survival time being 4 months for patients receiving everolimus and 1.9 months for those receiving placebo.
Side effects of the drug included mouth sores, rash and fatigue were more common in the everolimus group but were found to be mild or moderate.
[Source: YahooNews]
The progression rate of the kidney cancer was found to be 37% in the everolimus group as compared to 65% in the placebo group with survival time being 4 months for patients receiving everolimus and 1.9 months for those receiving placebo.
Posted by: 花蓮 | January 11, 2009 3:02 AM | Permalink to Comment